Actively Recruiting
Phase 2 Study of Elritercept Alone or With Ruxolitinib for Adults With Myelofibrosis to Evaluate Safety and Effectiveness
Led by Takeda · Updated on 2026-02-05
135
Participants Needed
46
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and tolerability of an investigational drug called elritercept, both alone and in combination with the JAK inhibitor ruxolitinib, in adults with myelofibrosis MF. The study also aims to understand how elritercept affects the signs and symptoms of MF, how the body processes the drug, and its effects on anemia when used with or without ruxolitinib. This is a Phase 2 open-label study focusing on participants with anemia related to MF.
CONDITIONS
Brief Title
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
